Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
35 studies found for:    " March 06, 2013":" April 05, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Recruiting Metabolomics Fingerprinting and Metabolic Dynamics After HIV Infection
Condition: HIV
Intervention:
2 Active, not recruiting Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)
Condition: HIV
Interventions: Behavioral: Social Network Intervention;   Behavioral: Counsel, Test, and Treat
3 Active, not recruiting
Has Results
Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: EFV/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI
4 Completed Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center
Condition: HIV Seropositivity
Interventions: Drug: Placebo;   Drug: Rouvastatin calcium
5 Completed
Has Results
Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools
Condition: HIV Infection
Intervention:
6 Completed Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
Condition: HIV Seropositivity
Intervention:
7 Active, not recruiting
Has Results
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions: HIV;   HIV Infections
Intervention: Drug: E/C/F/TAF
8 Completed A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects
Condition: HIV Infections
Intervention:
9 Recruiting Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Condition: HIV Infections
Intervention: Drug: Raltegravir
10 Completed Comparison of the QT/QTc Interval Between an Outpatient HIV-Infected Population on Antiretroviral Therapy and Two Large HIV-Negative Cohorts
Condition: QT and Corrected QT Intervals Prolongation in HIV Positive Subjects Treated With an Antiretroviral Regimen
Intervention:
11 Completed Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
Condition: HIV-infection/AIDS
Interventions: Drug: Cenicriviroc;   Drug: Dolutegravir;   Drug: Midazolam
12 Enrolling by invitation The "START" (a Streamlined ART Initiation Strategy) Study
Condition: HIV
Intervention: Behavioral: START
13 Recruiting Intervention Research to Reduce HIV Sexual Transmission Among HIV Positive Men Who Have Sex With Men
Condition: HIV
Interventions: Behavioral: Gay Poz Sex;   Other: Wait List/Standard of Care
14 Active, not recruiting Immune Enhancement for Immunological Non-responders to ART
Condition: HIV
Intervention: Dietary Supplement: Zinc and SAMe
15 Completed Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine
Condition: - HIV
Interventions: Biological: EN41-UGR7C HIV vaccine;   Biological: NaCl
16 Recruiting HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
Condition: HIV
Intervention: Drug: Atripla or Stribild
17 Withdrawn SCOPE: Strategies to Combine PrEP With Prevention Efforts
Condition: HIV
Intervention: Drug: Once daily Truvada®
18 Completed HCV Treatment in HIV Co-Infected Patients in Asia
Conditions: Hepatitis C;   HIV
Intervention: Drug: Pegylated-Interferon and Ribavirin
19 Completed Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services
Condition: HIV
Intervention: Behavioral: Conditional cash transfer
20 Unknown  Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders
Condition: HIV
Interventions: Drug: Triptolide;   Drug: cART;   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.